单时间点估算177Lu-PRRT吸收剂量对患者管理的影响:在159例患者和477个治疗周期中验证训练的多重线性回归模型
本研究回顾性分析159例患者(172次治疗、477个治疗周期)的177Lu-DOTATATE SPECT/CT数据,验证单时间点模型估算吸收剂量并与标准多时间点模型比较。结果显示两种模型在170/172次治疗(98.8%)中管理决策一致,各器官平均累积吸收剂量相对差异小且相关性高(Pearson r=0.99)。结论认为单时间点模型可简化剂量学流程、减少扫描仪和人员时间并提高患者舒适度。
要点
- 单时间点与多时间点模型在98.8%(170/172次治疗)的管理决策上一致。
- 肾脏、骨髓、肝脏、脾脏和肿瘤的平均累积吸收剂量相对差异分别为0.8%±8.0%、-7.7%±4.8%、0.0%±11.4%、-2.8%±6.3%和-2.1%±18.4%(Pearson r=0.99)。
- 单时间点模型可简化剂量学流程,减少扫描仪和人员时间并提高患者舒适度。
核心结论
- 单时间点与多时间点模型估算的辐射吸收剂量和患者管理决策相似。
- 单时间点模型可简化剂量学流程,同时减少扫描仪和人员时间并提高患者舒适度。
研究设计与样本
- 回顾性分析159例连续患者(172次治疗、477个治疗周期)的177Lu-DOTATATE SPECT/CT治疗后定量数据。
- 比较单时间点模型与多时间点模型获得的吸收剂量,并评估单时间点模型对因预期肾脏吸收剂量超过安全阈值而停止PRRT决策的影响。
- 假设单时间点模型与多时间点模型的患者管理在至少90%的病例中无差异。
主要发现
- 多时间点与单时间点模型的管理决策在172次治疗中的170次(98.8%)无差异。
- Fisher χ2检验合并概率产生复合P值为0.0003。
- 在完成4个治疗周期的患者中,单时间点与多时间点模型的平均累积吸收剂量相对差异分别为肾脏0.8%±8.0%、骨髓-7.7%±4.8%、肝脏0.0%±11.4%、脾脏-2.8%±6.3%、肿瘤-2.1%±18.4%,Pearson r均为0.99。
- 治疗周期较少时获得相似结果。
关键数值与推荐
- 单时间点模型预测吸收剂量所用治疗后研究采集时间为:首次输注后168小时,后续输注后24小时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dosimetry after 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) enables estimation of radiation doses absorbed by normal organs and target lesions. This process is time-consuming and requires multiple posttreatment studies on several subsequent days. In a previous study, we described a newly developed multiple-linear-regression model to predict absorbed doses (ADs) from a single-time-point (STP) posttreatment study acquired 168 h after the first infusion and 24 h after the following ones, with similar results to the standard multiple-time-point (MTP) protocol. The present study aimed to validate this model in a large patient cohort and to assess whether STP dosimetry affects patient management decisions compared with our MTP protocol. Methods: Quantitative 177Lu-DOTATATE SPECT/CT post-PRRT data from 159 consecutive patients (172 therapies, 477 therapy cycles) were retrospectively analyzed. ADs obtained from an STP model were compared with those obtained using an MTP model. We evaluated the impact of the STP model on the decision on whether PRRT should be stopped because of an expected kidney AD exceeding the safety threshold. We hypothesized that patient management based on the STP model does not differ from that based on the MTP model in at least 90% of the cases. Results: There was no difference in management decisions between the MTP and STP models in 170 of 172 therapies (98.8%). A Fisher χ2 test for combined probabilities produced a composite P value of 0.0003. Mean cumulative AD relative differences between the STP and MTP models were 0.8% ± 8.0%, -7.7% ± 4.8%, 0.0% ± 11.4%, -2.8% ± 6.3%, and -2.1% ± 18.4% for kidneys, bone marrow, liver, spleen, and tumors, respectively (Pearson r = 0.99 for all), for patients who underwent 4 therapy cycles. Similar results were obtained with fewer therapy cycles. Conclusion: Estimated radiation ADs and patient management decisions were similar with the STP and MTP models. The STP model can simplify the dosimetry process while also reducing scanner and staff time and improving patient comfort.
引用
- Chicheportiche A, Sason M, Zidan M, et al. Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles. J Nucl Med. 2023. PMID: 37500259. doi:10.2967/jnumed.122.264923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。